Updated: April 13, 2025
VTTWX
Vanguard Institutional Target Retirement 2030 Fund Institutional Shares
NASDAQ
28.83
-0.24
VIRSX
Vanguard Institutional Target Retirement 2040 Fund Institutional Shares
NASDAQ
30.89
-0.36
VTIP
Vanguard Short-Term Inflation-Protected Securities Index Fund
NASDAQ Global Market
48.87
0.01
Ticker
Market Cap
Revenue
EPS
PE Ratio
Volume
Dividend
Week Range
Beta
Frameworks
Name
Score
Company Overview
Country
Founded
IPO Date
industry
Employees
CEO
Top News
Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing Approval
Gilead Sciences shows strong growth in its HIV and oncology franchises, with BIKTARVY and TRODELVY driving significant revenue increases in 2024. LIVDELZI's conditional approvals in the U.S. and Europe for PBC treatment could boost the Liver Disease portfolio, despite risks tied to confirmatory trials. SUNLENCA could become the first twice-yearly HIV prevention medication, pending regulatory approvals in the U.S. and Europe, potentially enhancing the HIV franchise.
Gilead Dives As HHS Reportedly Mulls Cutting HIV Prevention Funding
Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' topline. The post Gilead Dives As HHS Reportedly Mulls Cutting HIV Prevention Funding appeared first on Investor's Business Daily.
Gilead Sciences Stock Slips on Possible HIV Funding Cut
Pharmaceutical stock Gilead Sciences Inc (NASDAQ:GILD) is down 2.6% at $107.34, after news that domestic HIV prevention is under review by the Trump administration, and the Health and Human Services Department could significantly cut funds.
Economic Moat Analysis
-
Scoring
1. 10Y Growth Analysis
Score: 0.0 (No rating available)
No summary available.
2. Scenario Analysis
Score: 0.0 (No rating available)
No summary available.
3. Risk & Opportunities
Score: 0.0 (No rating available)
No summary available.
4. Economic Moat
Score: 0.0 (No rating available)
No summary available.
5. Business Model
Score: 0.0 (No rating available)
No summary available.
6. Management Analysis
Score: 0.0 (No rating available)
No summary available.
7. BCG Matrix
Score: 0.0 (No rating available)
No summary available.
8. SWOT Analysis
Score: 0.0 (No rating available)
No summary available.
9. Porter's 5 Forces
Score: 0.0 (No rating available)
No summary available.
10. PESTLE Analysis
Score: 0.0 (No rating available)
No summary available.
11. ESG Analysis
Score: 0.0 (No rating available)
No summary available.
12. Company Milestones
Score: 0.0 (No rating available)
No summary available.
Final Overall Score
Score: 0.0
Future Outlook
No se pudo obtener el análisis para este framework.
No se pudo obtener el análisis para este framework.
No se pudo obtener el análisis para este framework.
No se pudo obtener el análisis para este framework.
No se pudo obtener el análisis para este framework.
No se pudo obtener el análisis para este framework.
No se pudo obtener el análisis para este framework.
No se pudo obtener el análisis para este framework.
No se pudo obtener el análisis para este framework.
No se pudo obtener el análisis para este framework.
No se pudo obtener el análisis para este framework.
No se pudo obtener el análisis para este framework.
9.0 – 10.0 Exceptional
Exceptional strengths and opportunities with minimal weaknesses and threats.
7.0 – 8.9 Strong
Significant strengths and opportunities outweigh weaknesses and threats.
4.0 – 6.9 Balanced
Equal strengths/opportunities and weaknesses/threats.
0.0 – 3.9 Weak
Weaknesses and threats significantly outweigh strengths and opportunities.
Metrics
Total Valuation
Market Cap
Enterprise Value
Net Debt
Shares
Shares Outstanding
Owned by Insiders (%)
Owned by Institutions (%)
Analysis Forecast
Price Target
Difference
Analyst Consensus
Analyst Count
Revenue Growth Forecast (5Y)
EPS Growth Forecast (5Y)
Dividends
Annual Dividend
Dividend Yield
Payout Ratio
Shares Buyback
Buyback Yield
Income Statements
Revenue
Gross Profit
Operating Income
Pretax Income
Net Income
EBITDA
Balance Sheet
Current Assets
Total Assets
Total Deb
Total Liabilities
Shareholder's Equity
Short Selling
Short Interest
Short % of Float
Short % of Shares Out
Cash Flows
Operating Cash Flow
Capital Expenditure
Free Cash Flow
Market Value
EPS
P/E Ration
Forward PE
PEG Ratio
P/B Ratio
P/S Ratio
P/FCF Ratio
E/V EBITDA
EV/ Sales
E/V FCF
Efficiency Ratios
Asset Turnover Ratio
Inventory Turnover Ratio
Accounts Receivable Turnover
CCC
Leverage Ratios
Debt to Equity Ratio
Debt to Assets (Debt Ratio)
Interest Coverage
Equity Ratio
Profitability Ratios
Return on Equity (ROE)
Return on Assets (ROA)
Return on Capital (ROIC)
WACC
WACC vs ROIC
Liquidity Ratios
Current Ratio
Quick Ratio
Working Capital
Margins
Gross Profit Margin
Net Profit Margin
EBITDA Margin
FCF Margin
Add to WatchList
Warning: Invalid argument supplied for foreach() in /var/www/html/invetso/wp-content/plugins/insert-php/includes/shortcodes/shortcode-php.php(60) : eval()'d code on line 174
Create New WatchList